Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are two profitable companies that balance growth and profitability and one that may face some trouble.
One Stock to Sell:
Portillo's (PTLO)
Trailing 12-Month GAAP Operating Margin: 5.1%
Begun as a Chicago hot dog stand in 1963, Portillo’s (NASDAQ: PTLO) is a casual restaurant chain that serves Chicago-style hot dogs and beef sandwiches as well as fries and shakes.
Why Do We Steer Clear of PTLO?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new restaurants
- Low free cash flow margin of -0.1% declined over the last year as its investments ramped, giving it little breathing room
- 7× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Portillo’s stock price of $4.22 implies a valuation ratio of 17.1x forward P/E. Read our free research report to see why you should think twice about including PTLO in your portfolio.
Two Stocks to Watch:
BioMarin Pharmaceutical (BMRN)
Trailing 12-Month GAAP Operating Margin: 9.7%
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ: BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Are We Fans of BMRN?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 14.5% annual sales growth over the last two years
- Exciting sales outlook for the upcoming 12 months calls for 28.4% growth, an acceleration from its two-year trend
- Free cash flow margin jumped by 5.6 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
BioMarin Pharmaceutical is trading at $56.66 per share, or 2.7x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free.
Accenture (ACN)
Trailing 12-Month GAAP Operating Margin: 14.4%
With a workforce of approximately 774,000 people serving clients in more than 120 countries, Accenture (NYSE: ACN) is a professional services firm that helps organizations transform their businesses through consulting, technology, operations, and digital services.
Why Do We Love ACN?
- Market share has increased this cycle as its 9.6% annual revenue growth over the last five years was exceptional
- Enormous revenue base of $72.11 billion provides significant distribution advantages
- Free cash flow margin expanded by 5.4 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
At $170.20 per share, Accenture trades at 12.2x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
